Literature DB >> 9508196

Extravesical tumor relapse in patients with superficial bladder tumors.

H W Herr1.   

Abstract

PURPOSE: To define the incidence of extravesical urothelial tumors among patients with high-risk superficial bladder tumors. PATIENTS AND METHODS: Three hundred seven patients with multiple recurrent papillary and in situ carcinomas of the bladder were treated with transurethral resection and intravesical bacillus Calmette Guérin (BCG) therapy and monitored for a median of 12 years (range, 10 to 18). Extravesical tumors were detected during investigation of a positive urine cytology after no tumor was found in the bladder.
RESULTS: Among 307 patients, 78 (25%) developed tumors in the upper urinary tract (UTT). Of 251 men, 61 (24%) had tumors detected in the prostatic urethra or ducts (T4p). The median times to detection of an UTT or prostatic epithelial tumor were 56 months and 11 months, respectively, and 32% of the UTT and 44% of the T4p relapses were lethal.
CONCLUSION: Patients with high-risk superficial bladder tumors who are treated successfully by a bladder-sparing strategy are at increased risk for tumor relapse that involves extravesical mucosa.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9508196     DOI: 10.1200/JCO.1998.16.3.1099

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  11 in total

Review 1.  Current problems and needs in the treatment of pT1 G3 bladder carcinoma.

Authors:  Francisco Jose Martínez Portillo; Peter Alken
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

2.  Bladder cancer: Always consider extravesical sites when BCG fails.

Authors:  Friedrich-Carl von Rundstedt; Seth P Lerner
Journal:  Nat Rev Urol       Date:  2013-12-17       Impact factor: 14.432

3.  Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?

Authors:  Thomasz Golabek; Joan Palou; Oscar Rodríguez; Josep Maria Gaya; Alberto Breda; Humberto Villavicencio
Journal:  World J Urol       Date:  2016-06-09       Impact factor: 4.226

4.  Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer.

Authors:  Aaron Brant; Marcus Daniels; Meera R Chappidi; Gregory A Joice; Nikolai A Sopko; Andres Matoso; Trinity J Bivalacqua; Max Kates
Journal:  World J Urol       Date:  2019-03-08       Impact factor: 4.226

5.  Case report: differential diagnosis of isolated iliac lymphadenopathy following Bacillus Calmette-Guérin treatment for high-risk superficial bladder cancer.

Authors:  Suzanne M Biers; Aimee Di Marco; A Hugh Mostafid
Journal:  Int Urol Nephrol       Date:  2007-03-13       Impact factor: 2.370

6.  Monitoring of the upper urinary tract in patients with bladder cancer.

Authors:  Rajinikanth Ayyathurai; Mark S Soloway
Journal:  Indian J Urol       Date:  2011-04

Review 7.  Immunotherapy for bladder cancer.

Authors:  Oliver Fuge; Nikhil Vasdev; Paula Allchorne; James Sa Green
Journal:  Res Rep Urol       Date:  2015-05-04

8.  Prostatic urethra recurrence after transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer (NMIBC).

Authors:  Vladimir Bilim; Senji Hoshi
Journal:  Clin Case Rep       Date:  2022-01-08

9.  Endourologic management of upper tract transitional cell carcinoma following cystectomy and urinary diversion.

Authors:  Jeffrey John Tomaszewski; Marc Christopher Smaldone; Michael Cecil Ost
Journal:  Adv Urol       Date:  2008-12-28

10.  Surgical Management of Upper Urinary Tract Urothelial Cell Carcinoma with Venous Tumor Thrombus: A Liver Transplant-Based Approach.

Authors:  Gaetano Ciancio; Marina M Tabbara; Melanie Martucci; Jeffrey J Gaynor; Mahmoud Morsi; Javier Gonzalez
Journal:  J Clin Med       Date:  2021-12-19       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.